Limits...
Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder.

Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M - Brain Behav. Immun. (2015)

Bottom Line: For these two inflammatory markers, there was moderate heterogeneity in study-specific estimates, subgroup differences were small, and publication bias appeared to be an unlikely explanation for the findings.Sensitivity analyses including only high-quality studies and subjects free of antidepressant medication further verified the associations.In conclusion, this cumulative meta-analysis confirmed higher mean levels of interleukin-6 and C-reactive protein in patients with major depression compared to non-depressed controls.

View Article: PubMed Central - PubMed

Affiliation: Department of Epidemiology and Public Health, University College London, London, UK; Finnish Institute of Occupational Health, Systems Toxicology Unit, Centre of Expertise for Health and Work Ability, Helsinki, Finland; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK. Electronic address: r.haapakoski@ucl.ac.uk.

No MeSH data available.


Related in: MedlinePlus

Cumulative meta-analysis for TNF-α levels and major depressive disorder.
© Copyright Policy - CC BY
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4566946&req=5

f0015: Cumulative meta-analysis for TNF-α levels and major depressive disorder.

Mentions: The pooled evidence showed increased blood levels of TNF-α in MDD patients (N = 31, combined d = 0.40, 95% CI = 0.15–0.65, total N(MDD) = 1214, total N(non-MDD) = 1262) (Fig. 3). The effect reached statistical significance (p < 0.05) after 14 studies in 2009 and the size of the association did not substantially change after the publication of 17 additional articles. Heterogeneity in study-specific effect estimates was high (Q = 254, p < 0.0001, I2 = 88%), suggesting that systematic differences existed between studies. There was no apparent publication bias (Begg and Mazumdar’s tau 0.22 (p = 0.08), Egger’s regression intercept 2.91 (p = 0.12).


Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder.

Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M - Brain Behav. Immun. (2015)

Cumulative meta-analysis for TNF-α levels and major depressive disorder.
© Copyright Policy - CC BY
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4566946&req=5

f0015: Cumulative meta-analysis for TNF-α levels and major depressive disorder.
Mentions: The pooled evidence showed increased blood levels of TNF-α in MDD patients (N = 31, combined d = 0.40, 95% CI = 0.15–0.65, total N(MDD) = 1214, total N(non-MDD) = 1262) (Fig. 3). The effect reached statistical significance (p < 0.05) after 14 studies in 2009 and the size of the association did not substantially change after the publication of 17 additional articles. Heterogeneity in study-specific effect estimates was high (Q = 254, p < 0.0001, I2 = 88%), suggesting that systematic differences existed between studies. There was no apparent publication bias (Begg and Mazumdar’s tau 0.22 (p = 0.08), Egger’s regression intercept 2.91 (p = 0.12).

Bottom Line: For these two inflammatory markers, there was moderate heterogeneity in study-specific estimates, subgroup differences were small, and publication bias appeared to be an unlikely explanation for the findings.Sensitivity analyses including only high-quality studies and subjects free of antidepressant medication further verified the associations.In conclusion, this cumulative meta-analysis confirmed higher mean levels of interleukin-6 and C-reactive protein in patients with major depression compared to non-depressed controls.

View Article: PubMed Central - PubMed

Affiliation: Department of Epidemiology and Public Health, University College London, London, UK; Finnish Institute of Occupational Health, Systems Toxicology Unit, Centre of Expertise for Health and Work Ability, Helsinki, Finland; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK. Electronic address: r.haapakoski@ucl.ac.uk.

No MeSH data available.


Related in: MedlinePlus